Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Paravasthu Mukund, Chief Operating Officer of NovoCure Ltd (NASDAQ:NVCR), recently executed a series of stock sales totaling $39,687. The transactions occurred on February 27 and 28, 2025, involving the sale of 2,014 ordinary shares. The sales come as NovoCure, currently valued at $2 billion, has seen its stock decline by 10% in the past week. According to InvestingPro analysis, the stock’s RSI indicates oversold conditions. The shares were sold at prices ranging from $18.2843 to $20.549. Following these transactions, Mukund holds 29,423 shares directly. This activity was detailed in a Form 4 filing with the Securities and Exchange Commission. The company’s current share price of $18.41 sits well below its 52-week high of $34.13, with InvestingPro offering 8 additional key insights about the company’s financial health and market position in its comprehensive Pro Research Report.
In other recent news, Novocure reported its fourth-quarter earnings, revealing a loss of $0.61 per share, which missed analyst expectations by $0.25. Despite this, the company exceeded revenue estimates with $161.26 million, surpassing the consensus of $153.04 million and marking a 21% year-over-year increase. For the full year 2024, Novocure’s total net revenues rose by 19% to $605.2 million, driven by the successful launch of Optune Gio for glioblastoma in France and improved approval rates in the U.S. The company also announced the FDA approval of Optune Lua for metastatic non-small cell lung cancer, with its commercial rollout underway in the U.S. Novocure’s Phase 3 PANOVA-3 trial met its primary endpoint, showing improved survival rates for patients with unresectable pancreatic cancer. As of the end of 2024, there were 4,126 active patients on TTFields therapy globally. The company concluded the year with $959.9 million in cash, cash equivalents, and short-term investments. Looking forward, Novocure anticipates growth in its glioblastoma business and expects gross margins to be affected by product enhancements and new launches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.